The Src pathway as a therapeutic strategy

Drug Discovery Today: Therapeutic Strategies

Volumn 2, Issue 4, 2005, Pages 313-321

  Belsches Jablonski, Allison P ^a,b   Demory, Michelle L ^b   Parsons, J Thomas ^b   Parsons, Sarah J ^b  

^a LYNCHBURG COLLEGE   (United States)

^b UNIVERSITY OF VIRGINIA HEALTH SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

17 ALLYLAMINO 17 DEMETHOXYGELDANAMYCIN; 2,3 DIHYDRO 2 OXO 3 (4,5,6,7 TETRAHYDRO 1H INDOL 2 YLMETHYLENE) 1H INDOLE 5 SULFONIC ACID DIMETHYLAMIDE; 4 (4' PHENOXYYANILLINO 6,7 DIMETHOXYQUINAZOLINE); 4 AMINO 7 TERT BUTYL 5 (4 CHLOROPHENYL)PYRAZOLO[3,4 D]PYRIMIDINE; 4 AMINO 7 TERT BUTYL 5 (4 METHYLPHENYL)PYRAZOLO[3,4 D]PYRIMIDINE; 4 ANILINOQUINAZOLINE DERIVATIVE; 6 (2,6 DICHLOROPHENYL) 8 METHYL 2 (3 METHYLTHIOANILINO) 8H PYRIDO[2,3 D]PYRIMIDIN 7 ONE; AP 22408; AZD 0530; AZM 475271; BOSUTINIB; CGP 77675; DASATINIB; EPIDERMAL GROWTH FACTOR RECEPTOR; GEMCITABINE; IMATINIB; PAXILLIN; PD 173952; PROTEIN KINASE INHIBITOR; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE KINASE INHIBITOR; PURINE; PYRAZOLE DERIVATIVE; PYRIMIDINE DERIVATIVE; PYRROLE DERIVATIVE; QUINOLINE; QUINONE DERIVATIVE; TERPHENYL DERIVATIVE; UCS 15A; UNCLASSIFIED DRUG; UNINDEXED DRUG;

BONE DISEASE; BONE METASTASIS; CARCINOGENESIS; CELL CULTURE; CELL FUNCTION; CELL MIGRATION; CELL PROLIFERATION; CELL SURVIVAL; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; DATA ANALYSIS; DRUG MECHANISM; DRUG SAFETY; DRUG SPECIFICITY; DRUG TOLERABILITY; DRUG USE; GASTROINTESTINAL STROMAL TUMOR; HUMAN; IC 50; NONHUMAN; OSTEOPOROSIS; PANCREAS CANCER; PROTEIN FUNCTION; PROTEIN TARGETING; REGULATORY MECHANISM; REVIEW; SIDE EFFECT;

EID: 31044441585     PISSN: 17406773     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ddstr.2005.11.005     Document Type: Review

References (42)

1. Ö. Alper et al. Novel insights into c-Src Curr. Pharm. Des. 1 2005 1119-1130
2. C.L. Abram and S.A. Courtneidge Src family tyrosine kinases and growth factor signaling Exp. Cell Res. 254 2000 1-13
3. R. Roskoski Src protein-tyrosine kinase structure and regulation Biochem. Biophys. Res. Commun. 324 2004 1155-1164
4. T.J. Boggon and M.J. Eck Structure and regulation of Src family kinases Oncogene 23 2004 7918-7927
5. R. Ishizawar and S.J. Parsons c-Src and cooperating partners in human cancer Cancer Cell 6 2004 209-214
6. M. Shupnik Crosstalk between steroid receptors and the c-Src receptor tyrosine kinase pathways: Implications for cell proliferation Oncogene 23 2004 7979-7989
7. M. Warmuth Src family kinases: Potential targets for the treatment of human cancer and leukemia Curr. Pharm. Des. 9 2003 2043-2059
8. S.M. Thomas and J.S. Brugge Cellular functions regulated by Src family kinases Annu. Rev. Cell Dev. Biol. 13 1997 513-609
9. c-src by 4-anilinoquinazolines Biochemistry 40 2001 7084-7091
10. S. Kansra et al. Src family kinase inhibitors block amphiregulin-mediated autocrine ErbB signaling in normal human keratinocytes Mol. Pharmacol. 67 2005 1145-1157
11. M.M. Moasser et al. Inhibition of Src kinases by a selective tyrosine kinase inhibitor causes mitotic arrest Cancer Res. 59 1999 6145-6152
12. C. Puder et al. Terphenylquinone inhibitors of the Src protein tyrosine kinase from Stilbella sp. J. Nat. Prod. 68 2005 323-326
13. S.V. Sharma et al. UCS15A, a non-kinase inhibitor of src signal transduction Oncogene 20 2001 2068-2079
14. C. Oneyama et al. UCS15A, a novel small molecule, SH3-domain-mediated protein-protein interaction blocking drug Oncogene 21 2002 2037-2050
15. Yang, J.C. et al. (2005) Src kinase inhibition of neuropeptide-induced androgen-independent prostate cancer. 96th Annual Mtg. of Amer. Assoc. Cancer Res. (A3180)
16. M.V. Yezhelyev et al. Inhibition of src tyrosine kinase as treatment for human pancreatic cancer growing orthotopically in nude mice Clin. Cancer Res. 10 2004 8028-8036
17. R. Thaimattam et al. 3D-QSAR studies on c-Src kinase inhibitors and docking analyses of a potent dual kinase inhibitor of c-Src and c-Abl kinases Bioorg. Med. Chem. 13 2005 4704-4712
18. J.M. Golas et al. SKI-606, a 4-anilino-3-quinolinecarbonitrile dual inhibitor of Src and Abl kinases, is a potent antiproliferative agent against chronic myelogenous leukemia cells in culture and causes regression of K562 xenografts in nude mice Cancer Res. 63 2003 375-381
19. J.M. Golas et al. SKI-606, a Src/Abl inhibitor with in vivo activity in colon tumor xenograft models Cancer Res. 65 2005 5358-5364
20. R.A. Blake et al. SU6656, a selective Src family kinase inhibitor, used to probe growth factor signaling Mol. Cell Biol. 20 2000 9018-9027
21. M. Severgnini et al. Inhibition of the Src and JAK kinases protects against lipopolysaccharide-induced acute lung injury Am. J. Respir. Crit. Care Med. 171 2005 858-867
22. J.H. Hanke et al. Discovery of a novel, potent and Src family-selective tyrosine kinase inhibitor J. Biol. Chem. 271 1996 695-701
23. J. Waltenberger et al. A dual inhibitor of platelet-derived growth factor β-receptor and src kinase activity potently interferes with motogenic and mitogenic responses to PDGF in vascular smooth muscle cells Circ. Res. 85 1999 12-22
24. D.D. Boyd et al. Combination of an src kinase inhibitor with a novel pharmacological antagonist of the urokinase receptor diminishes in vitro colon cancer invasiveness Clin. Cancer Res. 10 2004 1545-1555
25. M.S. Duxbury et al. Inhibition of src tyrosine kinase impairs inherent and acquired gemcitabine resistance in human pancreatic adenocarcinoma cells Clin. Cancer Res. 10 2004 2307-2318
26. M. Missbach et al. A novel inhibitor of the tyrosine kinase Src suppressed phosphorylation of its major cellular substrates and reduces bone resorption in vitro and in rodent models in vivo Bone 24 1999 437-449
27. M. Missbach et al. Substituted 5,7-dephenyl-pyrrolo[2,3d]pyrimindines: potent inhibitors of the tyrosine kinase c-Src Bioorg. Med. Chem. Lett. 10 2000 945-949
28. W. Shakespeare et al. structure-based design of an osteoclast-selective, nonpeptide src homology 2 inhibitor with in vivo antiresorptive activity PNAS 97 2000 9373-9378
29. Hennequin, L.F. et al. (2005) The discovery of AZD0530: A novel, oral, highly selective and dual-specific inhibitor of the Src and Abl family kinases. 96th Annual Mtg. of Amer. Assoc. Cancer Res. (A2537)
30. Herynk, M.H. et al. (2005) c-Src inhibition with AZD0530 reduces estrogen mediated growth and invasion in breast cancer cells expressing the K303R ERα mutant. 96th Annual Mtg. of Amer. Assoc. Cancer Res. (A264)
31. Hiscox, S. et al. (2005) Adhesion-independent focal adhesion kinase activation involves Src and promotes cell adhesion and motility in tamoxifen-resistant MCF-7 cells and is inhibited by the Src/Abl kinase inhibitor AZD0530. 96th Annual Mtg. of Amer. Assoc. Cancer Res. (A266)
32. Logie, A. et al. (2005) Pharmacokinetics, tissue distribution and anti-tumor activity of the Src/Abl kinase inhibitor AZD0530 in a rat xenograft model. 96th Annual Mtg. of Amer. Assoc. Cancer Res. (A5989)
33. Mullender, M.G. et al. (2005) Inhibition of osteoclastic bone resorption by the novel, potent, and selective c-Src/Abl kinase inhibitor, AZD0530. 96th Annual Mtg. of Amer. Assoc. Cancer Res. (A2923)
34. Eastell, R. et al. (2005) The effect of AZD0530, a highly selective, orally available Src/Abl kinase inhibitor, on biomarkers of bone resorption in healthy males. 2005 ASCO Annual Meeting (A3041)
35. Lockton, J.A. et al. (2005) Phase I ascending single and multiple dose studies to assess the safety, tolerability and pharmacokinetics of AZD0530, a highly selective, dual-specific Src-Abl inhibitor. 2005 ASCO Annual Meeting (A3125)
36. N.P. Shah et al. Overriding Imatinib resistance with a novel ABL kinase inhibitor Science 305 2004 399-401
37. Evans, T.R. et al. (2005) Phase I dose-escalation study of the src and multi-kinase inhibitor BMS-354825 in patients with GIST and other solid tumors. 2005 ASCO Annual Meeting (A3034)
38. L. Neckers Hsp90 inhibitors as novel cancer chemotherapeutic agents Trends Mol. Med. 8 Suppl. 2002 S55-S61
39. R.K. Ramanathan et al. Phase I pharmacokinetic-pharmacodynamic study of 17-(allylamino)-17-demethoxygeldanamycin (17AAG, NSC 330507), a novel inhibitor of heat shock protein 90, in patients with refractory advance cancers Clin. Cancer Res. 11 2005 3385-3391
40. M.P. Goetz et al. Phase I trial of 17-allylamino-17-demethoxygeldanamycin in patients with advanced cancer J. Clin Oncol. 23 2005 1078-1087
41. S.J. Parsons Src M. Schwab Encyclopedic Reference of Cancer 2001 Springer 841-843
42. T. Sawyer et al. Src inhibitors: Genomics to therapeutics Expert Opin. Invest. Drugs 10 2001 1327-1344